Sera Prognostics, Inc. Announces Unaudited Earnings Results for the third Quarter and nine Months Ended September 30, 2021
November 09, 2021 at 04:01 pm EST
Share
Sera Prognostics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2021. For the quarter, the company announced revenue of $23,000 compared to $5,000 a year ago. Loss from operations was $9,442,000 compared to $4,644,000 a year ago. Net loss and comprehensive loss was $9,859,000 or $0.39 per basic and diluted share compared to $5,072,000 or $3.30 per basic and diluted share a year ago.
For the nine months, the company announced revenue of $56,000 compared to $19,000 a year ago. Loss from operations was $22,848,000 compared to $13,217,000 a year ago. Net loss and comprehensive loss was $22,525,000 or $2.32 per basic and diluted share compared to $14,473,000 or $9.46 per basic and diluted share a year ago.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
